Company: TELO
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010298
Chunk: 19

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Item 8
Chunk 19
---
 regarding our cash flows for the periods presented:

    Three
    Months Ended March 31, 

    2025  
    2024 
  
    Net cash provided by (used
    in): 

    Operating activities 
    $(863,132) 
    $(1,939,415)
  
    Financing
    activities 
     -  
     5,212,498 
  
    Net
    change in cash 
    $(863,132  
    $3,273,083 

Net
Cash from Operating Activities

The
cash used in operating activities resulted primarily from our net losses, stock-based compensation expenses and changes in components
of accounts payable and prepaid expenses.

For
the three months ended March 31, 2025, operating activities used $0.9 million of cash, primarily due to a net loss of $2.2 million, stock
compensation costs of $1.4 million offset by $0.06 million change in accounts payable, accrued and prepaid expenses. Accounts payable,
accrued and prepaid expenses was primarily composed of research and development payables, consultant costs, insurance costs, legal and
accounting expenses.

For
the three months ended March 31, 2024, operating activities used $1.9 million of cash, primarily due to a net loss of $6.3 million, debt
issuance costs of $4.3 million offset by $0.02 million change in accounts payable, accrued and prepaid expenses. Accounts payable, accrued
and prepaid expenses was primarily composed of research and development payables, consultant costs, insurance costs, legal and accounting
expenses.

Net
Cash from Financing Activities

For
the three months ended March 31, 2025, there were no financing activities.

For
the three months ended March 31, 2024, financing activities provided $5.2 million of cash, resulting primarily from $5.8 million in proceeds
from sale of common stock, less offering costs, offset by $0.5 million payments to related parties, and $0.1 million of repayments under
related party line of credit.

Item
3. Quantitative and Qualitative Disclosures About Market Risk

We
are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act, and therefore are not required to provide the information
under this item per Item 305(e) of Regulation S-K.

Item
4. Controls and Procedures